Arvest Bank Trust Division trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 147,683 shares of the company’s stock after selling 2,486 shares during the quarter. Johnson & Johnson comprises 1.4% of Arvest Bank Trust Division’s holdings, making the stock its 18th biggest position. Arvest Bank Trust Division’s holdings in Johnson & Johnson were worth $21,543,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in the business. WoodTrust Financial Corp raised its holdings in shares of Johnson & Johnson by 4.2% in the 3rd quarter. WoodTrust Financial Corp now owns 46,335 shares of the company’s stock worth $5,995,000 after purchasing an additional 1,848 shares in the last quarter. Park Avenue Securities LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $2,939,000. Managed Asset Portfolios LLC raised its holdings in shares of Johnson & Johnson by 4.3% in the 3rd quarter. Managed Asset Portfolios LLC now owns 181,153 shares of the company’s stock worth $23,438,000 after purchasing an additional 7,535 shares in the last quarter. Lucia Wealth Services LLC raised its holdings in shares of Johnson & Johnson by 2.1% in the 3rd quarter. Lucia Wealth Services LLC now owns 131,950 shares of the company’s stock worth $17,072,000 after purchasing an additional 2,744 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Johnson & Johnson by 10.0% in the 3rd quarter. Parallel Advisors LLC now owns 31,912 shares of the company’s stock worth $4,129,000 after purchasing an additional 2,911 shares in the last quarter. Institutional investors own 67.28% of the company’s stock.
In related news, Director Hubert Joly acquired 5,000 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $141.28 per share, with a total value of $706,400.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $706,400. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 2,017 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $141.07, for a total transaction of $284,538.19. Following the transaction, the executive vice president now directly owns 51,736 shares in the company, valued at $7,298,397.52. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.
JNJ has been the topic of a number of research reports. Raymond James dropped their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Credit Suisse Group reiterated a “buy” rating and issued a $163.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 31st. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a report on Wednesday, December 18th. Finally, Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $159.33.
JNJ stock opened at $146.52 on Wednesday. Johnson & Johnson has a 52-week low of $125.00 and a 52-week high of $147.84. The company’s 50 day simple moving average is $142.86 and its 200-day simple moving average is $134.74. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. The firm has a market capitalization of $381.78 billion, a P/E ratio of 17.91, a P/E/G ratio of 2.33 and a beta of 0.71.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. During the same quarter in the previous year, the business earned $2.05 earnings per share. The firm’s revenue was up 1.9% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 8.66 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.59%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is the Consumer Price Index (CPI)?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
